(Q44699279)

5 December 2017

title

Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor (English)

1 reference

5 December 2017

1 reference

Tarundeep Kakkar

1

1 reference

5 December 2017

Cynthia Sung

2

1 reference

5 December 2017

Leonid Gibiansky

3

1 reference

5 December 2017

Thuy Vu

4

1 reference

5 December 2017

Adimoolam Narayanan

5

1 reference

5 December 2017

Shao-Lee Lin

6

1 reference

5 December 2017

Michael Vincent

7

1 reference

5 December 2017

Christopher Banfield

8

1 reference

5 December 2017

Alex Colbert

9

1 reference

5 December 2017

Sarah Hoofring

10

1 reference

5 December 2017

Marta Starcevic

11

1 reference

5 December 2017

Peiming Ma

12

1 reference

5 December 2017

language of work or name

1 reference

21 May 2011

1 reference

5 December 2017

published in

Pharmaceutical Research

1 reference

5 December 2017

volume

28

1 reference

5 December 2017

issue

10

1 reference

5 December 2017

page(s)

2530-2542

1 reference

Biologic therapies for the treatment of asthma

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

Requirement for IL-13 independently of IL-4 in experimental asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

Interleukin-13: central mediator of allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

Complex role of the IL-4 receptor alpha in a murine model of airway inflammation: expression of the IL-4 receptor alpha on nonlymphoid cells of bone marrow origin contributes to severity of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

An IL-13 promoter polymorphism associated with increased risk of allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

Approximations of the target-mediated drug disposition model and identifiability of model parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

Population pharmacokinetics of infliximab in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

Physiologically-based PK/PD modelling of therapeutic macromolecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

Vascular and interstitial barriers to delivery of therapeutic agents in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

Population Pharmacokinetic Data Analysis of Cilobradine, an I f Channel Blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

Dimeric immunoglobulin E serves as a unit signal for mast cell degranulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0481-Y

Role of common cytokine receptor gamma chain (gamma(c))- and Jak3-dependent signaling in the proliferation and survival of murine mast cells

21 January 2018

1 reference

12 December 2020

Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects

1 reference

12 December 2020

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer

1 reference

12 December 2020

A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma

1 reference

12 December 2020

A cluster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children

1 reference

12 December 2020

Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity

1 reference

12 December 2020

10.1007/S11095-011-0481-Y

Identifiers

DOI

1 reference

5 December 2017

1 reference